Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Dengue
Interventions
Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Viral Infection
Interventions
UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg, UV-4B 90 mg, UV-4B 180 mg, UV-4B 360 mg, UV-4B 720 mg, UV-4B 1000 mg, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity

NCT01728792
Conditions
Dengue Fever
Interventions
TDV
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Syracuse, New York
Completed Phase 1 Interventional Accepts healthy volunteers

TDENV PIV and LAV Dengue Prime-boost Strategy

NCT02239614
Conditions
Dengue
Interventions
TDENV-LAV, TDENV-PIV 4 µg + alum adjuvant
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Dengue
Interventions
rDEN3/4delta30(ME), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Dengue Fever
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 11 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers Results available

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

NCT04786457
Conditions
Dengue
Interventions
Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Dengue
Interventions
Procleix Dengue Virus Assay
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
Not listed
Enrollment
150,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

NCT05048875
Conditions
Dengue
Interventions
Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Conditions
Dengue
Interventions
rDEN2Δ30-7169 vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT03999996
Conditions
Dengue Fever
Interventions
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
13 Years to 63 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
8
States / cities
Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
Conditions
Dengue Fever
Interventions
TAK-003, Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Huntsville, Alabama • Anaheim, California • Boise, Idaho + 11 more
Conditions
Healthy Volunteers
Interventions
AV-1, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Study of HBV-001 D1 in Healthy Adults

NCT00936429
Conditions
Dengue Fever
Interventions
DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel), Placebo for DEN1-80E
Biological
Lead sponsor
Hawaii Biotech, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Dengue Virus
Interventions
Investigational Vaccine for Dengue Virus Subtype 2, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Conditions
Dengue
Interventions
TetraVax-DV-TV003 (TV003), rDEN2Δ30-7169 (DENV-2), rDEN3Δ30 (DENV-3), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Conditions
Dengue
Interventions
rDEN3∆30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Completed Phase 1 Interventional Accepts healthy volunteers

Expansion of a Dengue-1 Live Virus Human Challenge

NCT03869060
Conditions
Dengue
Interventions
Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Interventions
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
7
States / cities
Alabaster, Alabama • Sacramento, California • Jacksonville, Florida + 4 more
Conditions
Dengue
Interventions
Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Dengue Virus
Interventions
Investigational Vaccine for DEN1, Placebo injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Burlington, Vermont
Completed No phase listed Observational Accepts healthy volunteers

Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol

NCT01226173
Conditions
Mass Screening
Interventions
Bio-Rad Platelia Dengue NS1 Ag test
Device
Lead sponsor
Bio-Rad Laboratories
Industry
Eligibility
16 Years and older
Enrollment
182,353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Lauderhill, Florida
Withdrawn Phase 1 Interventional Accepts healthy volunteers

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

NCT03110952
Conditions
Dengue
Interventions
TDENV-PIV, TDENV-F17, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Syracuse, New York